

CureVac – Focus Shift to Second-Generation mRNA Technology

October 12th, 2021

Forward-Looking Statements


The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.


Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Today's Evolving COVID-19 Situation



WHO WEEKLY UPDATE
SEP 27 TO OCT 3*




Pandemic vaccines

- Availability of licensed vaccines
- Global large scale vaccination efforts
- Managing peak demand for large populations

Differentiated vaccines

- Multivalent vaccines
- Combination vaccines
- Single-use formats
- Scalable manufacturing

Changes in Vaccine Demand and Urgency



Evolution of SARS-CoV-2

- Gradual transition from pandemic to endemic COVID-19

Development progress of second-generation program

- Late-stage development of second-generation candidates in mid-2022

Change in medical need

- CureVac estimates earliest potential approval for CVnCoV in mid-2022

Withdrawal
of first-generation
CVnCoV
from regulatory
approval process



Advanced Purchase Agreement with the European Commission (EC)

- Initial goal to employ CVnCoV to address acute pandemic need not given anymore
- Following CVnCoV regulatory withdrawal, the agreement ceases
- CureVac remains in contact with the EC and supportive of its public health efforts

FINANCIAL BUFFER

€196 million

Grant of the German
Federal Ministry of
Education and Research



€450 million

Upfront Payment
European Commission



FINANCIAL COMMITMENTS



Manufacturing:
CDMO network



Inventory:
Raw materials



Investment:
Property, Plant &
Equipment

Adapt Manufacturing Capabilities to Medical Need

NETWORK STREAMLINING

SHIFTING PRODUCTION FOCUS

CREATING PROCESS INDEPENDENCE

Change in Demand

- Remove pandemic demand peak of 2021 and first half of 2022
- Align capacity with actual medical needs for second-generation vaccine

Leverage Network Flexibility

- CVnCoV stopped, production shift to second-generation program
- Flexibly address variant specific and modified mRNA constructs

New Capabilities

- Enhanced formulation capabilities
- Continue GMP IV buildup for commercial scale manufacturing



mRNA
production




mRNA
formulation



Fill & Finish




Packaging



- **Joined forces** in collaboration agreements in July 2020/February 2021 for broad range of infectious diseases and COVID19 respectively
- **Tightening the collaboration** with an extension to the collaboration agreements committing large number of experts
- **Shifting gears** in the joint development with undivided focus, priority and resource allocation

CV2CoV Preclinical Data: Strong Immune Activation in Non-Human Primates* (1/2)


Neutralizing antibodies, Pseudovirus assay*



- CV2CoV, **faster onset** of neutralizing antibody production. High titers already two weeks after first dose
- CV2CoV, **10-times higher** neutralizing antibody induction compared to CVnCoV at peak level after 6 weeks
- Two-dose vaccination schedule of a **12µg dose** on day 0 and day 28

CV2CoV Preclinical Data: Strong Immune Activation in Non-Human Primates* (2/2)

Neutralizing antibodies, Pseudovirus assay



- CV2CoV, **higher titers** of strong cross-neutralizing antibodies
- Superior performance of CV2CoV against **relevant variants** compared to CVnCoV



Medical need shifting toward differentiated second-generation vaccines following changes in vaccine demand and urgency



Withdrawal of CVnCoV: reflecting changes in public health needs in ongoing transition from pandemic to endemic COVID-19



CureVac and GSK to focus priorities and resources to accelerate second-generation program for COVID-19 and other infectious diseases



Anticipated start of enrollment for clinical study with first representative, CV2CoV within next months



GSK's expertise and CureVac's deep roots in mRNA technology: prime position to play a prominent role in tackling future public health challenges